Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002895 (
sickle cell disease
)
11,747
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Surface-mediated reactions of clotting were compared in 21 black children with homozygous
sickle cell disease
, 12 age-matched controls, and 15 adults. Both the coagulant and antigen titers of Hageman factor (factor XII) were decreased in asymptomatic patients compared with those in the control groups. These findings were associated with slight but significant reductions in the plasma titers of prekallikrein and high molecular weight
kininogen
. A further decrease from the initially low titers of these contact factors was observed during vaso-occlusive crises. Additionally, we observed a disparate relationship between Hageman factor coagulant activity and its antigen titers. These data provide evidence for reduction of the contact factors in patients with homozygous
sickle cell disease
.
...
PMID:Reduction of contact factors in sickle cell disease. 384 65
Eight patients with
sickle cell anemia
(SS hemoglobin) were found to have decreased plasma levels of
kininogen
compared to normal control subjects. The
kininogen
level of the patients with
sickle cell anemia
was decreased further during sickle cell crises. The results suggest that components of the kinin system are profoundly affected in patients with
sickle cell anemia
, and during crises may play a role in the clinical presentation of patients.
...
PMID:Reduced plasma kininogen concentration during sickle cell crisis. 663 22
Sickle cell disease
(
SCD
) is an inherited monogenic red blood cell disorder affecting millions worldwide.
SCD
causes vascular occlusions, chronic hemolytic anemia, and cumulative organ damage such as nephropathy, pulmonary hypertension, pathologic heart remodeling, and liver necrosis. Coagulation system activation, a conspicuous feature of
SCD
that causes chronic inflammation, is an important component of
SCD
pathophysiology. The key coagulation factor, thrombin (factor IIa [FIIa]), is both a central protease in hemostasis and thrombosis and a key modifier of inflammation. Pharmacologic or genetic reduction of circulating prothrombin in Berkeley sickle mice significantly improves survival, ameliorates vascular inflammation, and results in markedly reduced end-organ damage. Accordingly, factors both upstream and downstream of thrombin, such as the tissue factor-FX complex, fibrinogen, platelets, von Willebrand factor, FXII, high-molecular-weight
kininogen
, etc, also play important roles in
SCD
pathogenesis. In this review, we discuss the various aspects of coagulation system activation and their roles in the pathophysiology of
SCD
.
...
PMID:Role of the coagulation system in the pathogenesis of sickle cell disease. 3164 37